Skip to main content
. 2019 Sep 26;45(1):235–237. doi: 10.1038/s41386-019-0505-6

Fig. 1.

Fig. 1

Psychosis is a defining characteristic of schizophrenia, schizoaffective disorder, and psychotic bipolar disorder, all mechanistically complex syndromes. These clinical syndromes were not distinguishable by the B-SNIP biomarker panel, with >70 individual biomarkers. Psychosis subjects, therefore, were combined into a single group, independent of conventional diagnosis. Then, biomarker variables were used to define subgroups with shared neurobiological variance. Two biomarker dimensions, “cognitive control” and “sensorimotor reactivity,” provided a means for creating biomarker-defined subgroups (called psychosis Biotypes). Biotype-1, -2, and -3 had distinctive neurobiological characteristics, including on variables not used in their definition (external validators). Within each Biotype, the level of cognition (see color intensity) can vary from low to high. Neural characteristics as they segregate in these groups could be the basis for distinct molecular and therapeutic targets